|
|
Article: Several Hybridon Presentations Highlight Early Cancer Platform.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
Hybridon Inc. was busy at the 94th American Association for Cancer Research meeting in Washington, highlighting early stage products.
Its synthetic immunomodulatory oligonucleotides (IMO) were the focus of two presentations, showing that in preclinical studies the compounds demonstrated immunological activity and antitumor activity. More specifically, results showed the IMO compounds have a Th-1-type cytokine induction profile in cell-based assays following in vivo administration in mice.
Selected IMO compounds showed in vivo activity in syngeneic melanoma in a MetaMouse model and in human tumor xenografts in mice of ...